Anti-ageing company seeks £3 million on AIM

Investment opportunity

CapRegen Ltd, established to make investments in anti-ageing and regenerative medicine products, is seeking to join the Alternative Investment Market in London, raising £3 million.

The London-based company says it wants to fund researchers with early-concept technologies that have short-term commercial viability. To do this it will steer away from technologies that are regulated by the FDA or the European regulators. Typically, non-regulated technologies will tend to be one to three years from commercialisation, while and investments in regulated technologies will tend to be five to seven years from market.

CapRegen is looking for new technologies under development in university laboratories, and says that, at least initially, it expects to find these in North America, although it would make investments around the world if appropriate. The company hopes to make several investments rather than focussing on just one or two.